美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

冠軍工業

0.0001

0.0000

成交量：- -

成交額：- -

市值：5.59

市盈率：0.00

高：0.0001

開：0.0001

低：0.0001

收：0.0001

52周最高：0.0001

52周最低：0.0001

股本：5.59萬

流通股本：- -

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-23.0334

每股收益(LYR):-23.0334

淨資產收益率：-49.45%

總資產收益率：-1.87%

市淨率：0.00

市盈率(LYR):0.00

資料載入中...

總覽公司新聞公告

港股異動 | 復宏漢霖(02696)漲超3% 近日HLX14獲歐洲藥品管理局CHMP積極評審意見

復宏漢霖(02696)：地舒單抗生物類似藥HLX14(重組抗RANKL全人單克隆抗體注射液)獲歐洲藥品管理局(EMA)人用醫藥產品委員會(CHMP)積極審評意見

吉利德科學升2.3% 公司HIV預防藥獲CHMP加速審批

羅氏：將繼續與歐洲藥品管理局就Elevidys療法合作

Sarepta股價下跌，因Elevidys未獲歐盟監管機構支持

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/CHMP/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CHMP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CHMP\",,,,,undefined,":{"symbol":"CHMP","market":"US","secType":"STK","nameCN":"冠軍工業","latestPrice":0.0001,"timestamp":1756411200000,"preClose":0.0001,"halted":0,"volume":0,"delay":15,"floatShares":0,"shares":55857,"eps":-23.033406,"marketStatus":"已收盤","change":0,"latestTime":"08-28 16:00:00 EDT 延時","open":0.0001,"high":0.0001,"low":0.0001,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-23.033406,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1756454400000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"EXPERT","adjPreClose":0.0001,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CHMP\",,,,,undefined,":{"symbol":"CHMP","floatShares":0,"roa":"-1.87%","roe":"-49.45%","lyrEps":-23.033406,"shares":55857,"dividePrice":0,"high":0.0001,"amplitude":0,"preClose":0.0001,"low":0.0001,"week52Low":0.0001,"pbRate":"0.00","psRate":"0.00","week52High":0.0001,"institutionHeld":0,"latestPrice":0.0001,"eps":-23.033406,"divideRate":0,"volume":0,"delay":15,"ttmEps":-23.033406,"open":0.0001,"prevYearClose":0.0001,"prevWeekClose":0.0001,"prevMonthClose":0.0001,"prevQuarterClose":0.0001,"fiveDayClose":0.0001,"twentyDayClose":0.0001,"sixtyDayClose":0.0001},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CHMP\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CHMP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CHMP\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CHMP\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2555608579","title":"港股異動 | 復宏漢霖(02696)漲超3% 近日HLX14獲歐洲藥品管理局CHMP積極評審意見","url":"https://stock-news.laohu8.com/highlight/detail?id=2555608579","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555608579?lang=zh_tw&edition=fundamental","pubTime":"2025-07-29 10:30","pubTimestamp":1753756255,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖涨超3%，截至发稿，涨3.31%，报71.9港元，成交额3831.84万港元。消息面上，复宏汉霖发布公告，近日，HLX14获欧洲药品管理局人用医药产品委员会积极审评意见，推荐批准HLX14的上市许可申请。CHMP的审评意见将会被递交至欧盟委员会，EC将参考该意见并在未来2-3个月做出最终审查决定。一旦获得EC批准，HLX14的集中上市许可将在所有欧盟成员国及欧洲经济区国家冰岛、列支敦士登和挪威生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1322964.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02696","BK4087","CHMP","BK1161"],"gpt_icon":0},{"id":"2554877836","title":"復宏漢霖(02696)：地舒單抗生物類似藥HLX14(重組抗RANKL全人單克隆抗體注射液)獲歐洲藥品管理局(EMA)人用醫藥產品委員會(CHMP)積極審評意見","url":"https://stock-news.laohu8.com/highlight/detail?id=2554877836","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554877836?lang=zh_tw&edition=fundamental","pubTime":"2025-07-28 18:17","pubTimestamp":1753697873,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖(02696)发布公告，近日，HLX14获EMA人用医药产品委员会(Committee for Medicinal Products for Human Use，“CHMP”)积极审评意见，推荐批准HLX14的上市许可申请。CHMP的审评意见将会被递交至欧盟委员会(European Commission，“EC”)，EC将参考该意见并在未来2-3个月做出最终审查决定。一旦获得EC批准，HLX14的集中上市许可将在所有欧盟成员国及欧洲经济区(EEA)国家冰岛、列支敦士登和挪威生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1322684.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","BK4081","EMA","02696","BK1515","BK4087","BK1574","CHMP","BK1161","159938"],"gpt_icon":0},{"id":"2554795973","title":"吉利德科學升2.3% 公司HIV預防藥獲CHMP加速審批","url":"https://stock-news.laohu8.com/highlight/detail?id=2554795973","media":"金吾资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554795973?lang=zh_tw&edition=fundamental","pubTime":"2025-07-25 22:59","pubTimestamp":1753455573,"startTime":"0","endTime":"0","summary":"金吾财讯 | 吉利德科学(GILD)股价上扬，截至发稿，涨2.31%，报115.81美元。公司今日宣布，欧洲药品管理局（EMA）下属人用药品委员会（CHMP）已通过加速审评程序出具积极审评意见，推荐该公司HIV-1衣壳抑制剂注射剂lenacapavir用于暴露前预防（PrEP），以降低存在HIV-1感染风险的成年及青少年群体经性行为感染该病毒的概率。最终审批决定预计于今年晚些时间公布，若获批上市，该药物将以商品名Yeytuo®在欧盟地区销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072523004094bad418&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072523004094bad418&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CHMP","IE00B19Z3B42.SGD","LU0109394709.USD","LU0889565916.HKD","LU0320765992.SGD","LU2089984988.USD","LU1778281490.HKD","LU1674673691.USD","BK4550","BK4585","IE00B19Z3581.USD","BK4532","LU1430594728.SGD","IE00BSNM7G36.USD","LU1674673428.USD","IE00B7SZLL34.SGD","GILD","IE00BZ1G4Q59.USD","LU1571399168.USD","LU1585245621.USD","SG9999015986.USD","LU2324357040.USD","LU2087621335.USD","BK4588","IE0002270589.USD","IE00BKVL7J92.USD","BK4566","LU0289739699.SGD","LU0234570918.USD","LU2468319806.SGD","BK4139","BK4578","LU1066051498.USD","BK4087","SG9999015945.SGD","LU0058720904.USD","SG9999015952.SGD","LU1066053197.SGD","LU1839511570.USD","LU0823416689.USD","BK4583","SG9999015978.USD","IE00B3T34201.USD","BK4568"],"gpt_icon":0},{"id":"2554728761","title":"羅氏：將繼續與歐洲藥品管理局就Elevidys療法合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2554728761","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554728761?lang=zh_tw&edition=fundamental","pubTime":"2025-07-25 19:20","pubTimestamp":1753442456,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4589","CHMP","BK4588","BK4207","BK4081","CMA","EMA","BK4211","BK4585","159891","BK4087"],"gpt_icon":0},{"id":"2554616117","title":"Sarepta股價下跌，因Elevidys未獲歐盟監管機構支持","url":"https://stock-news.laohu8.com/highlight/detail?id=2554616117","media":"英为财情","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554616117?lang=zh_tw&edition=fundamental","pubTime":"2025-07-25 19:08","pubTimestamp":1753441680,"startTime":"0","endTime":"0","summary":"Investing.com -  Sarepta  Therapeutics Inc. 股价周五下跌13%，此前欧洲监管机构建议不批准该公司用于治疗杜氏肌营养不良症的基因疗法Elevidys。欧洲药品管理局的药物咨询委员会周五宣布，拒绝批准Elevidys用于治疗3至7岁能够行走的儿童。这一挫折紧随美国食品药品监督管理局最近要求暂停在美国使用Elevidys之后。Sarepta本周早些时候已宣布暂时停止在美国的出货。在美国和欧洲市场的双重监管挫折，对Sarepta的Elevidys商业化战略构成了重大挑战，该产品此前被定位为这种衰弱性疾病的突破性治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://cn.investing.com/news/stock-market-news/article-2903281","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"investing_news","symbols":["BK4087","CHMP","IE0009355771.USD","IE00BJJMRZ35.SGD","SRPT","IE00BFTCPJ56.SGD","IE0002141913.USD","BK4585","IE00BJT1NW94.SGD","BK4139","IE00B2B36J28.USD"],"gpt_icon":1}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}]}}